Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC33062 JH-VIII-157-02 JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells. JH-VIII-157-02 Chemical Structure
  3. GC63925 JH-X-119-01 JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 Chemical Structure
  4. GC18168 JI-101

    CGI1842

    An orally active inhibitor

     JI-101 Chemical Structure
  5. GC65436 JND3229 JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. JND3229 Chemical Structure
  6. GC18030 JNJ 28871063 hydrochloride ErbB receptor family inhibitor JNJ 28871063 hydrochloride Chemical Structure
  7. GC38502 JNJ-10198409 A potent PDGF tyrosine kinase inhibitor JNJ-10198409 Chemical Structure
  8. GC14544 JNJ-10198409 inhibitor of platelet-derived growth factor (PDGF-BB) tyrosine kinase JNJ-10198409 Chemical Structure
  9. GC12585 JNJ-38877605 C-Met inhibitor,ATP-competitive JNJ-38877605 Chemical Structure
  10. GC33266 JNJ-38877618 JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively. JNJ-38877618 Chemical Structure
  11. GC32995 JNJ-47117096 hydrochloride (MELK-T1 hydrochloride)

    MELK-T1 hydrochloride

     JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM. JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) Chemical Structure
  12. GC69318 JNJ-61803534

    JNJ-61803534 is an effective and orally active RORγt inverse agonist with an IC50 of 9.6 nM. It has anti-inflammatory activity and inhibits the production of IL-17A in human CD4+ T cells under Th17 differentiation conditions.

     JNJ-61803534 Chemical Structure
  13. GC69321 JTE-952

    JTE-952 is an orally active, type II selective inhibitor of colony-stimulating factor-1 receptor (CSF-1R/cFMS) that effectively inhibits CSF1R and TrkA with IC50 values of 13 nM and 261 nM, respectively. It can be used for research related to arthritis.

     JTE-952 Chemical Structure
  14. GC11362 K 252a

    SF 2370

     A protein kinase inhibitor K 252a Chemical Structure
  15. GN10497 Kaempferitrin

    BRN 0073958, Grosvenorine II, Kaempferol 3,7-O-α-Dirhamnoside, Lespedin

     Kaempferitrin Chemical Structure
  16. GC17638 KB SRC 4 KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity. KB SRC 4 Chemical Structure
  17. GC32625 KDR-in-4

    KDR-in-4

     KDR-in-4 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM. KDR-in-4 Chemical Structure
  18. GC63943 KH-CB20 KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and the closely related isoform CLK4, with an IC50 of 16.5 nM for CLK1. KH-CB20 Chemical Structure
  19. GC13264 Ki20227

    Ki 20227;Ki-20227

     A c-Fms kinase inhibitor Ki20227 Chemical Structure
  20. GC11666 Ki8751 VEGFR-2 inhibitor,potent and selective Ki8751 Chemical Structure
  21. GC13902 KRCA 0008 Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor KRCA 0008 Chemical Structure
  22. GC12590 KRN 633 VEGFR inhibitor,ATP-competitive KRN 633 Chemical Structure
  23. GC10626 KU14R KU14R Chemical Structure
  24. GC14592 KW 2449 A multi-kinase inhibitor KW 2449 Chemical Structure
  25. GC10523 KX1-004 Pp60c-src inhibitor KX1-004 Chemical Structure
  26. GC14288 KX2-391

    KX 01, Tirbanibulin

     KX2-391 (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. KX2-391 Chemical Structure
  27. GC10222 KX2-391 dihydrochloride A Src kinase inhibitor KX2-391 dihydrochloride Chemical Structure
  28. GC50137 KYL KYL, an antagonistic peptide, selectively targets EphA4 receptor. KYL Chemical Structure
  29. GC32044 L 601920-0 (Methyl-3β-hydroxycholenate) L 601920-0 (Methyl-3β-hydroxycholenate) is a ROR gamma modulator extracted from patent US20110263046 A1, in figure 2. L 601920-0 (Methyl-3β-hydroxycholenate) Chemical Structure
  30. GC44085 L-Sulforaphene

    Raphanin, (S)-Sulforaphene

     L-Sulforaphene, isolated from radish seeds, exhibits an ED50 against velvetleaf seedlings approximately 2 x 10-4 M. L-Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, p-ERK1/2, NF‐κB and other signals. L-Sulforaphene Chemical Structure
  31. GC36423 Lanraplenib

    GS-9876, GS-SYK

     A Syk inhibitor Lanraplenib Chemical Structure
  32. GC38630 Lanraplenib succinate

    GS-9876 succinate

     Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate Chemical Structure
  33. GC13608 Lapatinib

    GW572016; GW2016

     A dual inhibitor of EGFR and ErbB2 Lapatinib Chemical Structure
  34. GC25559 Lapatinib (GW-572016) Ditosylate

    GW-572016

     Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib (GW-572016) Ditosylate Chemical Structure
  35. GC16593 Lapatinib Ditosylate

    GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate

     Lapatinib Ditosylate is a selective dual inhibitor of ErbB-2 and EGFR with IC50 value against ErbB-2 and EGFR of 9.2 and 10.8 nM in vitro, respectively. Lapatinib Ditosylate Chemical Structure
  36. GC67759 Lapatinib-d4

    GW572016-d4; GW2016-d4

     Lapatinib-d4 Chemical Structure
  37. GC69356 Laprituximab

    J2898A

    Laprituximab (J2898A) is a humanized IgG1 antibody against EGFR that can be used to synthesize ADC IMGN289.

     Laprituximab Chemical Structure
  38. GC69358 Larotinib mesylate hydrate

    Larotinib mesylate hydrate is an effective, broad-spectrum, orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target, with an IC50 of 0.6 nM.

     Larotinib mesylate hydrate Chemical Structure
  39. GC16021 Lavendustin A

    NSC 678027, RG-14355

     EGFR tyrosine kinase inhibitor Lavendustin A Chemical Structure
  40. GC19218 Lazertinib

    YH25448

     Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. Lazertinib Chemical Structure
  41. GC13117 Lck Inhibitor

    Lymphocyte-specific Protein Tyrosine Kinase, RK-24466

     A selective inhibitor of lymphocyte-specific protein tyrosine kinase Lck Inhibitor Chemical Structure
  42. GC36430 Lck inhibitor 2 Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively Lck inhibitor 2 Chemical Structure
  43. GC14241 LDC1267 TAM kinase inhibitor,highly selective LDC1267 Chemical Structure
  44. GC14552 LDK378

    LDK 378;LDK-378;Ceritinib

     LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. LDK378 Chemical Structure
  45. GC17452 LDK378 dihydrochloride LDK378 dihydrochloride Chemical Structure
  46. GC50327 LDN 193189 dihydrochloride

    DM-3189

     Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs LDN 193189 dihydrochloride Chemical Structure
  47. GC33086 LDN-192960 LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively. LDN-192960 Chemical Structure
  48. GC44047 LDN-192960 (hydrochloride) LDN-192960 is an inhibitor of haspin protein kinase and dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) with IC50 values of 10 and 48 nM, respectively. LDN-192960 (hydrochloride) Chemical Structure
  49. GC38403 LDN-192960 hydrochloride LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively. LDN-192960 hydrochloride Chemical Structure
  50. GC16580 LDN-193189

    LDN 193189;LDN193189

     ALK inhibitor,potent and selective LDN-193189 Chemical Structure
  51. GC16798 LDN-211904 LDN-211904 (compound 32) is a potent and selective EphB3 inhibitor with an IC50 of 0.079 μM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC. LDN-211904 Chemical Structure
  52. GC17035 LDN-212854 BMP receptor inhibitor,potent and selective LDN-212854 Chemical Structure
  53. GC13225 LDN-214117 potent and selective ALK2 inhibitor LDN-214117 Chemical Structure
  54. GC14931 LDN193189 Hydrochloride

    LDN 193189 hydrochloride; LDN-193189 hydrochloride

     An inhibitor of BMP receptors ALK1, ALK2, ALK3, and ALK6 LDN193189 Hydrochloride Chemical Structure
  55. GC15454 Lenvatinib (E7080)

    E-7080, ER-203492-00

     Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. Lenvatinib (E7080) Chemical Structure
  56. GC36438 Lenvatinib mesylate

    E-7080

     An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate Chemical Structure
  57. GC17033 Lestaurtinib

    CEP-701; KT-5555

     A potent JAK2 and PRK1 kinase inhibitor Lestaurtinib Chemical Structure
  58. GC17958 Linifanib (ABT-869)

    Linifanib

     Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. Linifanib (ABT-869) Chemical Structure
  59. GC15749 Linsitinib

    OSI 906; OSI-906; OSI906

     IGF1R/IR inhibitor,potent and novel Linsitinib Chemical Structure
  60. GC47570 Lipoxygenin An inhibitor of 5-LO Lipoxygenin Chemical Structure
  61. GC17835 LM 22A4 tropomyosin-related kinase B (TrkB) agonist LM 22A4 Chemical Structure
  62. GC30770 LM22B-10 An activator of TrkB and TrkC LM22B-10 Chemical Structure
  63. GC36425 LOXO-101 (Larotrectinib)

    ARRY-470, Larotrectinib

     LOXO-101 (Larotrectinib) (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). LOXO-101 (Larotrectinib) Chemical Structure
  64. GC15282 LOXO-101 (Larotrectinib) sulfate LOXO-101 (Larotrectinib) sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). LOXO-101 (Larotrectinib) sulfate Chemical Structure
  65. GC19547 LOXO-292

    selpercatinib

     LOXO-292 (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. LOXO-292 has anticancer activity. LOXO-292 Chemical Structure
  66. GC65390 LRRK2 inhibitor 1 LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC50 of 6.8. LRRK2 inhibitor 1 Chemical Structure
  67. GC10809 LRRK2-IN-1

    Leucine-rich repeat kinase 2 IN-1

     A selective LRRK2 inhibitor LRRK2-IN-1 Chemical Structure
  68. GC69402 LRRK2-IN-7

    LRRK2-IN-7 is an effective, selective, CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. The selectivity of LRRK2-IN-7 is over 1000-fold for other kinases, ion channels and CYP enzymes.

     LRRK2-IN-7 Chemical Structure
  69. GC69410 Lumretuzumab

    Anti-Human ERBB3 Recombinant Antibody

    Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized monoclonal antibody that targets HER3 (ERBB3) and can be used for cancer research.

     Lumretuzumab Chemical Structure
  70. GC13848 LY2784544

    Gandotinib

     Potent inhibitor of JAK2 LY2784544 Chemical Structure
  71. GC11057 LY2801653

    Merestinib

     A MET kinase inhibitor LY2801653 Chemical Structure
  72. GC13424 LY2874455

    LY 2874455; LY-2874455

     A pan-FGFR inhibitor LY2874455 Chemical Structure
  73. GC40865 LYG-202 LYG-202 is a synthetic flavonoid with anticancer and anti-angiogenic activities. LYG-202 Chemical Structure
  74. GC69418 Lyn-IN-1

    Bafetinib analog

    Lyn-IN-1 (Bafetinib analog) is a highly active dual inhibitor of Bcr-Abl and Lyn.

     Lyn-IN-1 Chemical Structure
  75. GC62314 M4205 M4205 is a c-KIT inhibitor, with an IC50 of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17. M4205 Chemical Structure
  76. GC68304 Margetuximab Margetuximab Chemical Structure
  77. GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib mesylate Chemical Structure
  78. GC69436 Matuzumab

    EMD 72000

    Matuzumab (EMD 72000) is a humanized monoclonal antibody that can block EGFR activation and downstream signaling, inhibiting tumor growth.

     Matuzumab Chemical Structure
  79. GC66349 Mavrilimumab

    CAM 3001

     Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. Mavrilimumab Chemical Structure
  80. GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 Chemical Structure
  81. GC64583 MAX-40279 hemiadipate MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate Chemical Structure
  82. GC64582 MAX-40279 hemifumarate MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate Chemical Structure
  83. GC16483 MAZ51 VEGFR3 antagonist MAZ51 Chemical Structure
  84. GC64710 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate. MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Chemical Structure
  85. GC69460 Mefatinib

    Mifanertinib dimaleate

    Mefatinib is an effective tyrosine kinase inhibitor with anti-tumor activity.

     Mefatinib Chemical Structure
  86. GC69459 Mefatinib free base

    Mifanertinib

    Mefatinib free base is an effective tyrosine kinase inhibitor with anti-tumor activity.

     Mefatinib free base Chemical Structure
  87. GC14951 Meleagrin

    6-O-Methyloxaline

     antibiotic Meleagrin Chemical Structure
  88. GC36585 Merestinib dihydrochloride Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM). Merestinib dihydrochloride Chemical Structure
  89. GC68018 MET kinase-IN-2 MET kinase-IN-2 Chemical Structure
  90. GC12069 Methyl 2,5-dihydroxycinnamate

    Methyl 2,5dihydoxycinnamate

     EGF receptor-associated tyrosine kinases inhibitor Methyl 2,5-dihydroxycinnamate Chemical Structure
  91. GC36596 Methylnissolin

    (–)-Methylnissolin

     Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. Methylnissolin Chemical Structure
  92. GC13598 MGCD-265 MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity. MGCD-265 Chemical Structure
  93. GC61516 MID-1 MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 Chemical Structure
  94. GC32819 Mirk-IN-1 (Dyrk1B/A-IN-1)

    Dyrk1B/A-IN-1

     Mirk-IN-1 (Dyrk1B/A-IN-1) is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively. Mirk-IN-1 (Dyrk1B/A-IN-1) Chemical Structure
  95. GC16337 MK-2461 C-Met (WT/mutants) inhibitor MK-2461 Chemical Structure
  96. GC13140 MK-8033

    MK 8033;MK8033

     MK-8033 Chemical Structure
  97. GC36625 MK-8033 hydrochloride MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs). MK-8033 hydrochloride Chemical Structure
  98. GC47687 ML-209 An RORγt antagonist ML-209 Chemical Structure
  99. GC17582 ML347

    LDN193719

     BMP receptor inhibitor,potent and selective ML347 Chemical Structure
  100. GC30769 MLi-2 An LRRK2 inhibitor MLi-2 Chemical Structure
  101. GC10775 MLR 1023

    CP 26,154, NSC 314335

     MLR 1023 is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM. MLR 1023 Chemical Structure

Items 601 to 700 of 1157 total

per page
  2. 5
  3. 6
  4. 7
  5. 8
  6. 9

Set Descending Direction